Barry A Freedman

49243861, May 8, 1990

Jul 13, 1987

7/072943

Barry A. Freedman - Lincroft NJ
Marc S. Meketon - Middletown NJ
Robert J. Vanderbei - Morganville NJ

American Telephone and Telegraph Company - New York NY

G06F 1520

364402

A method and apparatus for optimizing resource allocations is disclosed which utilizes the Karmarkar algorithm to proceed in the interior of the solution space polytope. The values of the allocation variables are limited by upper and lower bounds, either individually or collectively with the same common bound. Each successive approximation of the solution point, and the polytope, are normalized such that the solution point is at the center of the normalized polytope using a diagonal matrix of the current solution point. The objective function is then projected into the normalized space and the next step is taken in the interior of the polytope, in the direction of steepest-descent of the objective function gradient and of such a magnitude as to remain within the interior of the polytope. The process is repeated until the optimum solution is closely approximated. The resulting algorithm steps are advantageously applied to linear programming problems which involve allocations which are simultaneously dependent on a large number of constraints, problems which might otherwise involve excessive amounts of computation time.

56278870, May 6, 1997

Feb 21, 1996

8/603525

Barry H. Freedman - Holmdel NJ

AT&T - Holmdel NJ

H04M 1700
H04M 1500
H04M 1506
H04M 164

379144

When a collect call is initiated by a calling party, and the call is routed to an operator services position, an automated attendant, or other system in the telephone network. In addition to playing an announcement to the called party to determine if he or she will accept the call, information is furnished to the called party, preferably by an announcement, indicating (a) the anticipated cost for the call, and, optionally, (b) the relative cost of the call, as compared to the cost that would be imposed if another carrier carried the call. This information may be obtained using the dialed number and information identifying the calling party location, and by querying a database containing (a) rate information, and optionally (b) comparative information setting forth the rates of different carriers offering collect call service in the same calling area. The invention can be practiced in an automated attendant, sometimes referred to as an interactive telecommunications services platform, which may be part of (a) a switch in a local exchange network, or (b) a switch in an interexchange (long distance) network. The collect calls may be originated by dialing a 0+call, or by calling a predetermined 800 number such as 1-800-CALL ATT.

58599029, Jan 12, 1999

May 6, 1997

8/851794

Barry H. Freedman - Holmdel NJ

AT&T Corp - Middletown NJ

H04M 1700
H04M 1500
H04M 1506
H04M 164

379144

When a collect call is initiated by a calling party, and the call is routed to an operator services position, an automated attendant, or other system in the telephone network. In addition to playing an announcement to the called party to determine if he or she will accept the call, information is furnished to the called party, preferably by an announcement, indicating (a) the anticipated cost for the call, and, optionally, (b) the relative cost of the call, as compared to the cost that would be imposed if another carrier carried the call. This information may be obtained using the dialed number and information identifying the calling party location, and by querying a database containing (a) rate information, and optionally (b) comparative information setting forth the rates of different carriers offering collect call service in the same calling area. The invention can be practiced in an automated attendant, sometimes referred to as an interactive telecommunications services platform, which may be part of (a) a switch in a local exchange network, or (b) a switch in an interexchange (long distance) network. The collect calls may be originated by dialing a 0+ call, or by calling a predetermined 800 number such as 1-800-CALL ATT.

20200399702, Dec 24, 2020

Jul 6, 2020

16/921287

- Boston MA, US
- Winston-Salem NC, US
Martin R. Pollak - Boston MA, US
Barry I. Freedman - Winston-Salem NC, US

C12Q 1/6883

Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject. The methods include detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with infection. The methods include detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with (such as , or ). The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and/or a deletion of N388 and Y389 to the subject.

20180105880, Apr 19, 2018

Nov 27, 2017

15/822994

- Boston MA, US
- Winston-Salem NC, US
Martin R. Pollak - Boston MA, US
Barry I. Freedman - Winston-Salem NC, US

C12Q 1/6883

Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject. The methods include detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with infection. The methods include detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with (such as , or ). The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and/or a deletion of N388 and Y389 to the subject.